Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maresin 2
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intrathecal, Intravenous, Subcutaneous
01
Overview
Maresin 2 (MaR2; 13R,14S-dihydroxy-docosahexaenoic acid) is an endogenous specialized pro-resolving mediator (SPM) biosynthesized from the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) by macrophages. Its biosynthesis is mediated by 12-lipoxygenase (12-LOX) and soluble epoxide hydrolase (sEH). Maresin 2 possesses potent anti-inflammatory, pro-resolving, and tissue-regenerative properties. It acts as an agonist of the leukotriene B4 receptor 1 (LTB4R/BLT1) and regulates downstream pathways including the upregulation of TREM2 in macrophages, suppression of the NLRP3 inflammasome, and activation of cardiac autophagy via ULK1 O-GlcNAcylation. Preclinical studies have demonstrated its therapeutic potential in mitigating cardiac inflammation and remodeling in diabetic cardiomyopathy, heart failure with preserved ejection fraction (HFpEF), and myocardial infarction, as well as promoting mucosal wound healing in colitis and alleviating inflammatory and neuropathic pain.
- Other names
- 13R,14S-diHDHA13R,14S-dihydroxy docosahexaenoic acid13R,14S-dihydroxy-4Z,7Z,9E,11E,16Z,19Z-docosahexaenoic acidMaR2MaR-2MaR 2maresin-2maresin2maresin 2
02
Targets
LTB4R (Leukotriene B4 Receptor 1)
Beyond the preview
Go deeper on maresin 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maresin 2.